#Vaccine production usa download#

Layered on top of this are the confirmed purchases for each vaccine. The interactive graph in Tab 1.1 displays 20 manufacturing projections by vaccine developer (grouped by vaccine platform). In 2022, we expect to see mRNA vaccines continue to dominate much of the supply but with Sinopharm and Sinovac significantly increasing manufacturing capacity of their inactivated virus vaccines. The 2021 supply will be dominated by Pfizer-BioNTech and Oxford-AstraZeneca. The capacity expansion is not evenly spread across vaccine makers, though.

To meet the global total of more than 12 billion doses projected in 2021, production will need to increase on a scale we have not seen before.

PRODUCTION CAPACITY FOR 20 VARIES WIDELY AMONG VACCINES AND VACCINE PLATFORMS Some countries may also choose to purchase and maintain surplus vaccine doses beyond their immediate needs in order to manage future risks, diminishing the immediate supply for other countries. The approval of one or more vaccines for children could shift the demand and supply landscape again. No vaccines are yet approved for use in children under 16 years of age, but several are being tested in children now. We also do not yet know how long immunity from vaccines will last and we may need regular booster shots to maintain immunity and to target new variants. For example, the emergence and spread of new variants may mean that we need a new generation of vaccines before the end of 2021. (It is worth noting that those are both big ifs.) If manufacturers are able to reach their goal of more than 12 billion doses this year and if those doses were purchased and distributed equitably across the world’s population, we could meet much of the world’s needs in 2021. This is frequently seen as the threshold to approach herd immunity, the level of vaccination coverage that limits spread and protects those who are unable to be vaccinated from infection. It is important to remember that this total is a sum of projections from vaccine developers and may include optimistic assumptions.Īssuming the market is primarily 2-dose vaccines (Janssen and CanSino are the only 1-dose vaccines currently on the market), about 11 billion doses are needed to vaccinate 70 percent of the world’s population. Our analysis of 2021 projections from Covid-19 vaccine makers indicates that more than 12 billion doses could be produced this year. VACCINE MAKERS PROJECT A GLOBAL TOTAL OF 12 BILLION DOSES OF COVID-19 VACCINE IN 2021 Please contact us with data or corrections that can improve the accuracy of this data set. We hope that by highlighting the data gaps, we will encourage others to join this effort and help to fill in missing data points and bring more clarity to a murky system. It is important to recognize that this data is not comprehensive, as there are still many unknowns, but we are aggregating the information that is available to enable better insights and decisions globally. Read our Issue Brief: Deciphering the Manufacturing Landscape for Covid-19 Vaccines.

To help address this challenge, we are now tracking and analyzing publicly available information on manufacturing by vaccine and location. Publicly available information on production is scarce and fragmented, making it difficult for policy- and decision-makers to fully understand the various supply chains involved, take stock of the risks, and take urgent action where it is most needed in this global effort. Countries are looking to production estimates and delivery schedules to understand what they will have and when.ĭespite the importance of manufacturing, the landscape itself is remarkably opaque. Now, as many countries roll out their vaccination campaigns, manufacturing and supply have become critical constraints for global access and equity. In late 2020 and early 2021, purchases were the primary marker of who would get vaccines and who would be left behind. Note that our manufacturing data is up-to-date as of Jand we are not further updating the data or webpage content at this time.

#Vaccine production usa download#

Download our manufacturing data as part of our vaccine updates here.